StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report issued on Monday morning. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets decreased their price target on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Trading Up 4.7 %

NovaBay Pharmaceuticals stock opened at $0.73 on Monday. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $9.08. The stock has a market capitalization of $3.60 million, a price-to-earnings ratio of -0.01 and a beta of 0.65. The stock has a 50 day moving average of $0.62 and a two-hundred day moving average of $0.76.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.